23.1 Interim Visit Preparation and Consent Review

Interim Visit Preparation and Consent Review

While Site Selection Visits (SSVs) evaluate institutional capability and Site Initiation Visits (SIVs) launch protocol operations, Interim Monitoring Visits represent the core ongoing operational workload of the CRA during the active clinical conduct phase. Monitoring is neither an informal check-in nor an adversarial confrontation; rather, it is a disciplined, systematic quality control and quality assurance function.

Effective monitoring detects emerging procedural non-compliance, prevents data corruption, reinforces Good Clinical Practice, and protects participant safety before minor deviations compound into systemic study failure.

The Three-Phase IMV Lifecycle

A successful monitoring visit requires systematic execution across three distinct chronological phases:

Phase 1: Pre-Visit Preparation

Effective monitoring begins well before the CRA arrives at the investigative site. Arriving on-site without rigorous preparation wastes limited on-site hours and creates operational blind spots. Pre-visit preparation comprises five mandatory steps:

1. Previous Visit Reconciliation: The CRA reviews the previous IMV monitoring report, the follow-up letter transmitted to the PI, and the site action item tracker. Every outstanding finding—such as an uncertified medical record, a missing laboratory normal range, or an unresolved pharmacy temperature excursion—is flagged for priority on-site re-examination.
2. EDC and Query Status Audit: The CRA inspects the electronic data capture (EDC) platform to identify pending site-level queries, query aging metrics (queries unresolved $>14$ or $>30$ days), unentered subject visits, and forms with outstanding investigator electronic signatures.
3. Protocol Deviation and Safety Screening: The CRA reviews the trial's centralized deviation log and safety database to identify site-specific patterns, such as missed pharmacokinetic draws, out-of-window visits, or discrepancies between site AE logs and safety pharmacovigilance reports.
4. Enrollment and Interactive Response Technology (IRT): The monitor reviews the IRT / Interactive Web Response System (IWRS) to determine newly screened, randomized, completed, or discontinued participants, ensuring that subject identification numbers match site tracking logs.
5. The Formal Confirmation Letter: At least 2 to 4 weeks prior to the visit (or per trial-specific monitoring plan timelines), the CRA transmits a written Confirmation Letter to the Principal Investigator and Lead Clinical Research Coordinator (CRC). This letter outlines:
   • Exact dates and arrival/departure times.
   • Purpose and primary objectives of the visit.
   • List of specific subject identification numbers whose medical charts must be pulled or made accessible in the Electronic Medical Record (EMR) system.
   • Specific facility access requirements (e.g., investigational pharmacy, biological specimen freezers, satellite clinics).
   • Mandatory appointment time for the Principal Investigator debrief / exit interview.

Phase 2: On-Site Visit Execution

Upon arrival, the monitor establishes a secure, professional workspace. The CRA meets briefly with the Lead CRC to review the day's agenda, confirm investigator availability, verify that requested medical records are unlocked in the EMR, and address immediate site operational questions. The monitor then systematically executes the monitoring workflow outlined below.

Phase 3: Post-Visit Follow-Up

Immediately following the visit, the CRA enters post-visit execution mode. The monitor drafts the formal monitoring report and follow-up letter, documents all identified deviations in the clinical trial management system (CTMS), and initiates tracking of corrective actions.

Step-by-Step On-Site Monitoring Activities

During an on-site visit, the CRA must execute a multi-layered audit across seven foundational clinical and operational domains:

Informed Consent Verification (Risk-Based Verification)

Informed consent is the ethical and legal cornerstone of human subject research. Under ICH E6(R3), obtaining freely given, documented informed consent prior to initiating any protocol-specific procedure is an absolute requirement.

• Verification coverage: Consent is critical to participant protection. Follow the justified monitoring plan; ICH does not prescribe a universal 100% SDV percentage. Every participant must still complete the applicable consent process before research activities.
• Critical Verification Checklist:
  • Version Currency: The monitor verifies that the ICF version signed by the subject was the version officially approved by the Institutional Review Board (IRB) / Independent Ethics Committee (IEC) at the exact date and time the consent was executed.
  • Signature and Date Authenticity: The monitor confirms that the participant (or their legally authorized representative [LAR], if applicable) personally signed and dated using the approved paper or electronic process the consent form. Pre-dating, back-dating, or coordinator-entered dates are critical GCP non-compliances.
  • Timing Verification: The CRA cross-references the exact timestamp of the signed consent document against the timestamps of the very first study-specific procedures (e.g., screening blood draws, protocol-mandated electrocardiograms, medication washouts). If any protocol-directed intervention occurred prior to obtaining documented consent, a major ethical and regulatory non-compliance has occurred.
  • Consent Process Note: The CRA audits the medical source record for a contemporaneous progress note documenting the consenting dialogue: that the trial was explained, risks and alternative therapies were discussed, the participant was given adequate time to consider participation, all questions were answered, and a signed, dated copy was provided to the participant.
  • Re-Consent Compliance: When protocol amendments introduce new safety information, altered visit schedules, or modified procedures, the monitor confirms that all active participants received timely new information and completed updated consent under the approved plan.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1.